Pharma Capsules - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma Capsules

Pharmaceutical Technology


Meisssner Launches New Website

Meissner Filtration Products (Camarillo, CA) recently launched its new website, http://www.meissner.com/. The new site highlights Meissner's line of laboratory products, including its "STyLUX" and "SteriLUX" 25-mm syringe filters and "Ultradyne" and "Steridyne" 50-mm vent filters. The site also describes Meissner's full-scale production elements such as "UltraCap" high-capacity capsules and "EverLUX" filter cartridges. The website allows users to access and download product literature easily. In addition, users can take a virtual manufacturing facility tour through a streaming video link.

ARx Opens Pharmaceutical Manufacturing Facility

ARx (Glen Rock, PA) officially opened its new pharmaceutical manufacturing facility 18 months after breaking ground. The 25,000-ft2 facility is designed to manufacture dissolvable film, transdermal, and buccal drug delivery systems for over-the-counter, prescription, and biopharmaceutical products. The globally-compliant facility triples ARx's manufacturing capacity and laboratory space.

ARx currently supports commercial thin-film products sold in the United States, Canada, and Latin America, including Novartis Consumer Health's "Triaminic" pediatric and infant cough and cold products, "Theraflu" cold and flu products, and "Gas-X" antigas relief products. The current facility increases the company's potential strip output to more than 1.4 billion strips per year.

ARx is a wholly owned subsidiary of Adhesives Research (Glen Rock, PA).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here